# Timeline of COVID Actions on REMS for Mifepristone

## March 23, 2020

FDA publishes <u>guidance</u> on REMS enforcement during public emergency. The policy allows providers to waive compliance with certain REMS, but not in-person dispensation requirements.

### March 30, 2020

The UK <u>temporarily allows</u> dispensation of mifepristone without in-person evaluation.

Attorneys General from 21 states ask the FDA to waive the REMS for mifepristone.

#### April 23, 2020

The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine submit a letter to the FDA requesting that the FDA suspend enforcement of the mifepristone REMS.

## May 27, 2020

The American College of Obstetricians and Gynecologists, Sister Song and others file suit against FDA requesting a temporary injunction of the in-person dispensing requirement during the public health emergency.

#### August 26, 2020

The federal government <u>appeals</u> the injunction to the Supreme Court of the United States.

#### January 12, 2021

The U.S. Supreme Court <u>stayed</u> the district court's injunction, allowing the federal government to enforce the in-person dispensing requirements of the mifepristone REMS. The case continues in the 4th Circuit.

## March 18, 2021

EMAA, ACLU, and a coalition of more than 55 reproductive health, rights, and justice organizations call on the Biden-Harris Administration to suspend the in-person dispensing requirement for the remainder of the public health emergency and initiate a full review of the mife REMS. Over 200,000 supporters joined the call to action by signing digital petitions.

#### May 2021

In a court filing, DOJ reveals FDA has initiated a full review of the mifepristone REMS.

January 31, 2020

US declares public emergency due to COVID-19.

March 25, 2020

The American Academy of Family Physicians <u>submits a letter</u> to the FDA supporting waiving the REMS for mifepristone.

April 14, 2020

Senators Murray, Warren and Baldwin write to the FDA regarding the REMS for mifepristone.

Anti-choice advocates submit <u>comments</u> to the docket advocating for continuing the REMS.

April 28, 2020

EMAA and more than 500 other advocates <u>submit</u> <u>comments</u> to the docket asking the FDA to waive some REMS for mifepristone.

July 13, 2020

The Court grants a temporary injunction to the in-person dispensing requirement for mifepristone.

October 8, 2020

The Supreme Court rejected the appeal and instructed the lower court to review the case within 40 days of receiving the government's filing.

February 9, 2021

Members of the House Oversight Committee sent a <u>letter</u> to Acting FDA Commissioner Dr. Janet Woodcock formally requesting that FDA lift the medically unnecessary in-person dispensing requirement for mifepristone.

April 12, 2021

FDA sent a <u>letter</u> to ACOG stating it will not enforce the in-person dispensing requirements of the mifepristone REMS for the remainder of the COVID-19 public health emergency, allowing for the mailing of mifepristone to resume as part of telehealth medication abortion care.